

# ADVAMED COVID-19 DIAGNOSTIC SUPPLY REGISTRY

AdvaMed members manufacture and ship instruments and high-quality tests that, together with key inputs from our colleagues across the testing ecosystem (e.g., PPE, plastics, swabs, etc.), serve as the backbone of supply for the U.S. testing response to COVID.

AdvaMed has created a national COVID-19 Diagnostic Supply Registry to support state and federal governments in their pandemic responses. AdvaMed and its members are fully committed to providing key data to policymakers and the public in our collective work mobilizing against the pandemic.

AdvaMed is leading this data tracking and analysis effort, driven by thirteen leading diagnostic manufacturers whose tests together comprise ~80-85% of the COVID-19 Molecular IVD tests on the market in the U.S.




## Key Data-Driven Summary of the U.S. COVID Testing Supply

Last updated March 26<sup>th</sup>, 2021

- Across leading COVID diagnostic manufacturers, **~411 million** molecular COVID-19 tests have been shipped since March, including **~318 million commercial tests** and **~93 million extraction reagents**.
- Per public sources, daily **Molecular tests run** decreased by 4% compared to the previous week, with an average of **~1.3 million<sup>2</sup>** tests per day last week.
- Registry participants collectively shipped **~6.8 million<sup>1</sup>** molecular tests for the week ending March 20<sup>th</sup>.
- High-quality **Serology testing**, authorized by the FDA, remains available at scale with industry **capacity to manufacture 100 million tests per month**.
- Registry participants have brought **Antigen testing** to market, though many states do not report antigen tests run.

## Weekly Molecular (MDx) tests shipped<sup>3</sup> & reported test results nationwide



1. Averaged over latest 4 weeks to account for fluctuations in purchase cycles. 2. Averaged over the week to account for fluctuations by day of the week. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests). 3. Weekly average over the last four weeks. 4. IVD and LDT molecular diagnostic test shipments. 5. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests).